CN1378448A - 多晶型托拉塞米 - Google Patents

多晶型托拉塞米 Download PDF

Info

Publication number
CN1378448A
CN1378448A CN00814045A CN00814045A CN1378448A CN 1378448 A CN1378448 A CN 1378448A CN 00814045 A CN00814045 A CN 00814045A CN 00814045 A CN00814045 A CN 00814045A CN 1378448 A CN1378448 A CN 1378448A
Authority
CN
China
Prior art keywords
torasemide
modification
type
solvent
dupont2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00814045A
Other languages
English (en)
Chinese (zh)
Inventor
J·阿伦希梅
D·莱奥诺夫
M·科尔多瓦
A·施瓦茨
B·-Z·多利茨基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN1378448A publication Critical patent/CN1378448A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Details Of Garments (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
CN00814045A 1999-08-11 2000-08-11 多晶型托拉塞米 Pending CN1378448A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14830599P 1999-08-11 1999-08-11
US60/148,305 1999-08-11
US18312700P 2000-02-17 2000-02-17
US60/183,127 2000-02-17
US21527300P 2000-06-30 2000-06-30
US60/215,273 2000-06-30

Publications (1)

Publication Number Publication Date
CN1378448A true CN1378448A (zh) 2002-11-06

Family

ID=27386674

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00814045A Pending CN1378448A (zh) 1999-08-11 2000-08-11 多晶型托拉塞米

Country Status (24)

Country Link
US (1) US6465496B1 (enExample)
EP (1) EP1207880A4 (enExample)
JP (1) JP2003527319A (enExample)
KR (1) KR20020025217A (enExample)
CN (1) CN1378448A (enExample)
AU (1) AU781461C (enExample)
BG (1) BG106400A (enExample)
CA (1) CA2379322A1 (enExample)
CZ (1) CZ2002404A3 (enExample)
DE (1) DE00957398T1 (enExample)
ES (1) ES2204354T1 (enExample)
HK (1) HK1046636A1 (enExample)
HR (1) HRP20020120A2 (enExample)
HU (1) HUP0204318A3 (enExample)
IL (1) IL148031A0 (enExample)
LT (1) LT5004B (enExample)
MX (1) MXPA02001369A (enExample)
NO (1) NO20020622L (enExample)
PL (1) PL354262A1 (enExample)
SI (1) SI20816A (enExample)
SK (1) SK1912002A3 (enExample)
TR (1) TR200200353T2 (enExample)
WO (1) WO2001010441A1 (enExample)
YU (1) YU9502A (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946379B (zh) * 2004-03-25 2012-05-16 菲尔若国际公司 含有托拉塞米和基质成型聚合物的延长释放组合物
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810A (zh) * 2022-09-22 2022-12-02 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK11632003A3 (sk) * 2000-02-17 2004-04-06 Teva Pharmaceutical Industries Ltd. Stabilný farmaceutický prípravok obsahujúci modifikáciu II torsemidu
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en) 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
EP1397343A1 (en) 2001-05-31 2004-03-17 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
IN192178B (enExample) 2001-08-03 2004-03-06 Ranbaxy Lab
US20030119882A1 (en) * 2001-10-22 2003-06-26 Markus Maegerlein Solid pharmaceutical composition containing torasemide
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
HRP20020603B1 (en) * 2002-07-19 2008-11-30 Pliva D.D. New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide
CA2424644A1 (en) * 2003-04-07 2004-10-07 David John Mckenzie Preparation of torasemide
AT500576B1 (de) * 2004-07-28 2006-11-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von kristallformen von torsemid
KR100845383B1 (ko) * 2004-12-24 2008-07-09 일동제약주식회사 토르세미드 변형체(ⅰ)의 제조방법
US20070122483A1 (en) * 2005-11-29 2007-05-31 Sharon Myers Fluocinolone acetonide drug substance polymorphic interconversion
AU2014348523B2 (en) 2013-11-15 2019-01-03 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30633A (en) 1860-11-13 Improvement in fire-escapes
US34672A (en) 1862-03-18 Improved convertible boat, bridge, and tent
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
US4055650A (en) 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
DE3623620A1 (de) 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
HRP20000162B1 (en) * 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
CA2403382A1 (en) * 2000-03-20 2001-09-27 Teva Pharmaceutical Industries Ltd. Novel processes for preparing torsemide intermediate
HRP20000328A2 (en) * 2000-05-19 2002-02-28 Pliva Farmaceutska Ind Dionik Novel polymorph v of torasemide

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946379B (zh) * 2004-03-25 2012-05-16 菲尔若国际公司 含有托拉塞米和基质成型聚合物的延长释放组合物
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810A (zh) * 2022-09-22 2022-12-02 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Also Published As

Publication number Publication date
ES2204354T1 (es) 2004-05-01
US6465496B1 (en) 2002-10-15
HUP0204318A3 (en) 2005-03-29
CA2379322A1 (en) 2001-02-15
JP2003527319A (ja) 2003-09-16
NO20020622L (no) 2002-03-14
IL148031A0 (en) 2002-09-12
MXPA02001369A (es) 2005-08-26
HK1046636A1 (zh) 2003-01-24
PL354262A1 (en) 2003-12-29
NO20020622D0 (no) 2002-02-08
CZ2002404A3 (cs) 2002-06-12
EP1207880A1 (en) 2002-05-29
AU781461B2 (en) 2005-05-26
AU781461C (en) 2006-02-23
SK1912002A3 (en) 2002-07-02
EP1207880A4 (en) 2004-09-01
WO2001010441A1 (en) 2001-02-15
LT2002017A (en) 2002-11-25
HUP0204318A2 (en) 2003-05-28
DE00957398T1 (de) 2004-04-15
TR200200353T2 (tr) 2002-06-21
HRP20020120A2 (en) 2003-10-31
LT5004B (lt) 2003-03-25
SI20816A (sl) 2002-08-31
BG106400A (en) 2002-08-30
KR20020025217A (ko) 2002-04-03
YU9502A (sh) 2005-06-10
AU6902600A (en) 2001-03-05

Similar Documents

Publication Publication Date Title
CN1378448A (zh) 多晶型托拉塞米
CN1245974C (zh) 卡维地洛
CN1678305A (zh) 卡维地洛磷酸盐和/或其溶剂合物和/或相应组合物和/或治疗方法
HU227625B1 (en) Modifications of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonyl-aminobenzene and processes for preparing them
CN1384816A (zh) 多晶型形式的盐酸舍曲林
CN1753874A (zh) 可用作肾上腺素受体激动剂的 5－′( r )－2－( 5 , 6－二乙基－茚满－2－基氨基)－1－羟基－乙基－8－羟基－(1h)－喹啉－2－酮盐的制备方法
CN1128261A (zh) 制备具有两种晶形的四唑衍生物的方法及所述衍生物的新晶形
CN1946688A (zh) 阿托伐他汀半钙的晶型
CN1055693C (zh) 生物可利用的结晶形式头孢呋辛酯
CN1861604A (zh) 阿色纳品马来酸盐的晶型
CN1181064C (zh) 结晶形式的n－(4－三氟甲基苯基)－5－甲基异噁唑－4－甲酰胺的制备方法
CN101039917A (zh) 制备替米沙坦的方法
CN1027503C (zh) 结晶4-(二正丙基)氨基-6-氨基羰基-1，3，4，5-四氢化苯并[cd]吲哚盐的制备方法
CN1434708A (zh) 新的盐酸舍曲林多晶型物、其制备方法、含有它们的组合物和应用它们的方法
CN110627791A (zh) 一种fascaplysin衍生物及制备方法
CN1874998A (zh) 1－苄基－4－[(5,6－二甲氧基－1－二氢茚酮)－2－基]甲基哌啶草酸盐(多奈哌齐草酸盐)及其多晶型物
CN1934108A (zh) 齐拉西酮碱的多晶型b2
CN1768057A (zh) 罗格列酮马来酸盐多晶型物的制备方法
CN1826318A (zh) 稳定的替加色罗马来酸氢盐变体
CN1314888A (zh) 奥沙奈丹的晶型
CN1305474A (zh) 帕罗西汀马来酸盐
CN1030077A (zh) 法莫丁啶多晶型物及其制备方法
CN1216036C (zh) 手性氨基醇配体及其在端炔对亚氨的不对称加成中的应用
CN1198821C (zh) 磺酰胺衍生物的制备方法及其晶体
CN1612874A (zh) 罗格列酮乙二磺酸盐和它们作为抗糖尿病药物的用途

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication